The muscle acetylcholine receptor (AChR) is the main target self-antigen in acquired autoimmune myasthenia gravis (MG). Here, we investigated an association of MG with the CHRND gene encoding the d-subunit of the AChR. Using a microsatellite repeat located in the second intron of the gene, we observed a preferential transmission of the allele 268 in 114 one-generation families with one myasthenic child (Pc ¼ 0.0154). This allele was also over-represented in a group of 350 unrelated nonthymoma MG patients (OR ¼ 1.78, P ¼ 0.038), but not in 84 thymoma patients, compared to 168 healthy controls. Moreover, among nonthymoma patients, those lacking serum anti-titin antibodies appeared to be best associated (OR ¼ 2.07, P ¼ 0.017). In contrast, there was no distortion in the transmission of a single-nucleotide substitution polymorphisms (SNPs) in the 3 0 untranslated region of CHRND nor in that of two SNPs located in the closely linked CHRNG gene, 4.5 kb telomeric to CHRND. The data warrant a detailed investigation of CHRND polymorphism in MG patients.
Acquired autoimmune myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction resulting in fatigability of striated muscles. [1] [2] [3] In most patients, it is caused by autoantibodies directed at the muscle acetylcholine receptor (AChR), a pentameric molecular complex made of four different subunits with stoichiometry a 2 bde in adult or a 2 bgd in embryonic muscle. 4, 5 As is the case for most autoimmune diseases, MG has a complex genetic control. 6 An HLA-linked locus has been characterized, but it explains the disease susceptibility only partly. 7 Given the central role of AChR in MG pathogenesis, the genes that encode AChR subunits are candidates for an analysis of the genetic factors that predispose to MG. On this basis, association and linkage of CHRNA1, the gene for the a-subunit of the AChR, were demonstrated previously. 8, 9 Here, we have investigated the role of the CHRND gene that encodes the d-subunit of the AChR. This gene is also a candidate of great interest. The d-subunit displays immunogenic epitopes for both B and T cells. [10] [11] [12] It interacts with the a-subunit to form a heterodimer in the first step of AChR assembly in muscle cells. 13 In contrast, it is expressed at a very low level in the thymus and it seems to be excluded from the AChR complexes that are formed in this organ, which plays an essential role in tolerance induction and in MG pathogenesis. 14, 15 Finally, the importance of the d-subunit in muscle AChR structure and function was demonstrated by the observation of congenital myasthenic syndromes that are caused by mutations in the CHRND gene. 16, 17 The CHRND gene is located on chromosome 2q37.1 and consists of 12 exons spanning 9.3 kb (Figure 1 ). To investigate an association with MG, we selected a (GA)n microsatellite repeat, CHRND_MS, located in its second intron (The Genome Database: GDB:439020) and three single nucleotide substitution polymorphisms (SNPs) that were described in dbSNP (build 96). Two of the SNPs, rs1004432 and rs1550093, are in the last intron and the third one, rs2767, is in the 3 0 untranslated region. Genotyping of the CHRND_MS microsatellite was conducted as described, 18 except that one of the oligonucleotide primers that was used for amplification was tagged with a fluorescent label. Amplification products were migrated on an ABI 373XL automated sequencer (Applied Biosystems, Foster City, CA, USA). Alleles were determined with the Genescan and Genotyper software and designated by their size in base pairs. SNPs were characterized by multiplexing single-base chain extension reactions, using the SNaPshot system (Applied Biosystems). All markers were in HardyWeinberg equilibrium.
A transmission-disequilibrium test (TDT) 19 was performed in 114 one-generation Caucasoid families with one child affected with MG. Transmission was assessed as implemented in the Genehunter software. 20 Cases with one missing parent were included only when the genotyped parent and the proband were both distinct heterozygotes. 21 For 64 patients, both parents could be genotyped. For 50 other patients, one parent was available. Altogether, 98 parents were heterozygous for CHRND_MS and 83 were informative for TDT. Heterozygous single parents exhibited CHRND_MS genotypes reflecting allele frequencies observed in the control population, including 260/262 (n ¼ 3), 262/264 (n ¼ 1), 262/266 (n ¼ 10), 262/268 (n ¼ 1), 258/266 (n ¼ 2), 264/ 266 (n ¼ 1) and 266/268 (n ¼ 4). As shown in Table 1 , the CHRND_MS*268 allele was transmitted to 16 children and untransmitted in three cases (Pc ¼ 0.0154). In contrast, transmission of rs2767 alleles was balanced (17 transmitted vs 16 untransmitted), whereas rs1004432 and rs155093 were not polymorphic in our population sample. Two-locus TDT disclosed a preferential transmission of the MS_268 allele combined to the 'C' allele of rs2767, with a borderline significance (eight transmissions vs one nontransmission, corrected P ¼ 0.056 for four haplotypes tested). Altogether, the data demonstrated linkage of CHRND to MG, with a positive association of CHRND_MS*268.
A case-control study comparing 444 unrelated Caucasoid patients and 168 healthy control subjects was then performed ( Table 2 ). The patient group included the 114 probands of the family-based analysis and 330 additional unrelated patients. They were included in the study with their written informed consent and in keeping with the tenets of the Declaration of Helsinki. They fulfilled clinical and electromyographic diagnostic criteria of acquired generalized MG. Moreover, as the CHRND gene was a candidate, all the patients had confirmed positive titers of anti-AChR autoantibodies (40.6 nM), determined with a radioimmunoprecipitation assay. 22 In 282 patients who underwent thymectomy, histopathology of the thymus was assessed as described elsewhere. 7 Patients with a thymoma were considered as a separate group. As a whole, they present a different clinical profile, often with severe clinical symptoms and they require specific treatments. [1] [2] [3] In addition, in contrast to nonthymoma patients, they showed no genetic association, whether at the HLA complex 7 or at the CHRNA1 locus (Giraud et al, submitted for publication). The control groups included 111 volunteering Caucasian a Exact probabilities were calculated using the binomial distribution. They were corrected by multiplication by the number of alleles tested, including six alleles for the microsatellite (the allele 270 cannot yield significant results) and one allele for the rs2767 SNP. The only P-value o0.05 reported corresponded to a nominal Pvalue of 0.0022. Table 3 .
(Supplemental Table) and were therefore pooled ( Table 2 ). As shown in Table 2 , nonthymoma patients showed a modest but significant increase in the frequency of CHRND_MS*268, compared with healthy control subjects (14.9 vs 8.9%, OR ¼ 1.78, P ¼ 0.038). Owing to the prior knowledge of an association of this allele, the Pvalue was tested one-sided and was not corrected for the number of alleles. The frequencies of other alleles, inferred from phenotype frequencies, were similar to those, transmitted or untransmitted, observed in the TDT analysis (Table 1) . In contrast, patients with thymoma showed no association with the allele 268, providing further support for thymoma patients being a pathogenetically distinct subset of MG patients.
The group of nonthymoma patients by itself was also heterogeneous. Probands of the family-based analysis were significantly younger at onset of disease than the additional cases (mean7s.d.: 29.2711.6 vs 46.6720.7 years, Po1 Â 10 À12 ). The former were more significantly associated with the CHRND_MS*268 allele than the whole group, whereas the latter showed no association (Table 3) . Other alleles were not distributed differently between the two subsets (Supplemental Table) . The age at onset of disease was not the actual discriminating parameter as the presence of the CHRND_MS*268 allele did not influence the age at onset (nonparametric MannWhitney test comparing nonthymoma patients positive and those negative for the allele 268, not significant). We and others have previously shown that, among nonthymoma patients, patients expressing anti-titin antibodies in their serum formed a characteristic subset with a late onset of disease and with intermediate titers of antiAChR antibodies. 22 Moreover, these patients showed specific HLA associations, positive with DR7 and negative with DR3.
7 Anti-titin antibodies had been assayed in 294 patients out of the 350 nonthymoma patients. Seven out of the 57 TDT probands (12.3%) and 86 out of 237 additional cases (36.3%) who were tested displayed serum anti-titin antibodies. As previously described, patients with anti-titin antibodies had a much later onset of disease (63712 years) than those without the antibodies (34.9717.2 years, Po1 Â 10
À16
). The whole sample showed frequencies for CHRND_MS alleles similar to those of the whole group of nonthymoma patients (Supplemental Table) . As shown in Table 3 , there was a modest but significant increase of the allele 268. Moreover, patients negative for anti-titin antibodies, but not those positive, now showed a significant association with the allele 268, with an odds ratio of 2.07 (P ¼ 0.017). Other alleles were similarly distributed (Supplemental Table) . Altogether, the data indicated that the association of the CHRND_MS*268 allele was restricted to the subset of MG patients lacking anti-titin antibodies and confirmed that patients expressing these antibodies form a distinct subset, both clinically and genetically.
Dinucleotide repeats may adopt an unusual conformation that may alter gene expression, as was recently demonstrated for a CA repeat in the nucleolin gene. 23, 24 However, given the complex properties of linkage disequilibrium, a thorough analysis of the polymorphism of CHRND and of neighbor loci along with functional studies will be necessary to establish the CHRND_MS microsatellite as a causative polymorphism in MG predisposition.
The CHRNG gene that encodes the g-subunit of AChR is situated at 4.5 kb on the telomeric side of CHRND (Figure 1 ). Two SNPs, rs1190434 and rs1656389, both localized in the fifth intron of CHRNG and separated by 13 bp, were selected among five available in dbSNP (build 96) and were typed in the 444 patients. Not surprisingly, pairwise linkage disequilibria between the various loci were highly significant (Po1 Â 10
À6
). However, the linkage disequilibrium D 0 measure 25, 26 between CHRND_MS and rs2767 (the CHRND SNP), and that between the two CHRNG SNPs were close to the unity, in marked contrast with the values of D 0 for pairwise associations between CHRND and CHRNG polymorphisms (Figure 1 ). These data suggested that although CHRND and CHRNG were closely linked, historical recombinations or evolutionary forces had individualized the two genes. Finally, a TDT with the CHRNG SNPs was performed in the sample of 114 one-generation families. Transmission of alleles of both SNPs was balanced (data not shown).
In conclusion, our study demonstrates linkage and association of the CHRND locus with MG. It will be essential to investigate different patient samples to obtain confirmation of the results. The data nevertheless warrant a detailed characterization of CHRND and CHRNG gene polymorphisms in MG patients. They also strengthen the interest for the genes encoding selfantigens in the analyses of a genetic predisposition to autoimmune diseases.
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